Citadel Advisors
AKTX

Citadel Advisors’s Akari Therapeutics AKTX Stock Holding History

Citadel Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
+10,000
New +$86.3K ﹤0.01% 12687

Other funds holding AKTX

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $673M AUM 55.24% 1-Year Est. Return

Citadel Advisors's AKTX Position: Q4 2024 in Review

Citadel Advisors sold out of Akari Therapeutics (AKTX) in Q4 2024, closing a stake of 832 shares — an estimated $99.1K sold.

Citadel Advisors first reported a position in AKTX in Q1 2015 and held it in 9 quarters. The position peaked at $99.1K in Q3 2024. 11 funds tracked by Wall St. Rank hold AKTX as of Q4 2024.

  • Citadel Advisors reported no remaining Akari Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 832 Akari Therapeutics shares in Q4 2024, an estimated $99.1K.
  • Citadel Advisors first reported a position in Akari Therapeutics in Q1 2015 and held it in 9 quarters.
  • Citadel Advisors's Akari Therapeutics position peaked at $99.1K in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Akari Therapeutics as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.